Log in

Relevant bibliographies by topics / Microangiopathic Anemia

Contents

Journal articles
Dissertations / Theses
Book chapters
Conference papers

Academic literature on the topic 'Microangiopathic Anemia'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Microangiopathic Anemia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Microangiopathic Anemia"

1

Brocklebank, Vicky, Katrina M. Wood, and David Kavanagh. "Thrombotic Microangiopathy and the Kidney." Clinical Journal of the American Society of Nephrology 13, no. 2 (2017): 300–317. http://dx.doi.org/10.2215/cjn.00620117.

Full text

Abstract:

Thrombotic microangiopathy can manifest in a diverse range of diseases and is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ injury, including AKI. It can be associated with significant morbidity and mortality, but a systematic approach to investigation and prompt initiation of supportive management and, in some cases, effective specific treatment can result in good outcomes. This review considers the classification, pathology, epidemiology, characteristics, and pathogenesis of the thrombotic microangiopathies, and outlines a pragmatic approach to diagnosis and

APA, Harvard, Vancouver, ISO, and other styles

2

Bhawna, Gondwal. "Thrombotic Microangiopathic Haemolytic Anaemia: A Pathologic Abnormality Associated with Diverse Clinical Syndromes." British Journal of BioMedical Research 1, no. 4 (2017): 217–22. https://doi.org/10.24942/bjbmr.2017.165.

Full text

Abstract:

A pathological process of microvascular thrombosis, microangiopathic hemolytic anemia and thrombocytopenia, with ischemia and infraction, affecting particularly kidney and brain is Thrombotic microangiopathy  (TMA). Disseminated intravascular coagulation (DIC) is caused by severe infectious disease and systemic inflammatory syndrome (SIRS). Thrombotic microangiopathy  (TMA) a rare but devastating disease, also known as microangiopathic hemolytic anemia (MAHA) in combination with thrombocytopenia and signs of organ damage. These pathological features are included in different clinical

APA, Harvard, Vancouver, ISO, and other styles

3

Todorović, Željko, and Marko Anđelić. "Thrombotic microangiopathy as the first manifestation of disseminated malignant disease." Srpski medicinski casopis Lekarske komore 3, no. 4 (2022): 492–98. http://dx.doi.org/10.5937/smclk3-40946.

Full text

Abstract:

Introduction: Thrombotic microangiopathies are a group of diseases characterized by disseminated intravascular thrombosis, thrombocytopenia and ischemic organ damage. This group includes thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. One of the causes of thrombotic microangiopathy, although rare, can also be malignant diseases, primarily cancers of the stomach, prostate, breast and lungs. Case report: We present a patient with thrombotic microangiopathy and disseminated malignant disease of unclear etiology. Conclusion: This clinical entity is called carcinoma-associated th

APA, Harvard, Vancouver, ISO, and other styles

4

Ikushima, Eigo, Manabu Hisahara, Takuya Nishijima, et al. "Atypical Hemolytic Uremic Syndrome following Acute Type A Aortic Dissection." Case Reports in Hematology 2020 (March 4, 2020): 1–4. http://dx.doi.org/10.1155/2020/2467953.

Full text

Abstract:

Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA)-related disease that manifests as a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI) and is caused by uncontrolled activation of the complement system. We report the case of a 61-year-old woman with acute type A aortic dissection that subsequently developed into aHUS. The hematologic disorders underlying aHUS improved after treatment with the complement inhibitor eculizumab. It is important to consider aHUS when a patient clinically develops a triad of microangiopathic hem

APA, Harvard, Vancouver, ISO, and other styles

5

Wasekar, Nilesh, and Shivani Joshi. "Interesting cases of microangiopathic hemolytic anemia." Medicover Journal of Medicine 1, no. 4 (2024): 172–75. https://doi.org/10.4103/mjm.mjm_38_24.

Full text

Abstract:

Microangiopathic hemolytic anemia (MAHA) is a type of hemolytic anemia where there is fragmentation and hemolysis due to damage of erythrocytes in the small blood vessels. The initial evaluation is focused on confirming MAHA and thrombocytopenia and excluding systemic disorders that manifest these findings/mimic thrombotic thrombocytopenic purpura. All patients with a suspected primary thrombotic microangiopathy should have a thorough laboratory workup. ADAMTS13 activity is measured before starting therapeutic plasma exchange (TPE). The immediate management decision is whether to perform TPE o

APA, Harvard, Vancouver, ISO, and other styles

6

Lee, Eric H., Salman Otoukesh, Amir Abdi pour, and Gayathri Nagaraj. "Hemolytic Anemia of Malignancy: A Case Study Involving Signet Ring Cell Metastatic Breast Cancer with Severe Microangiopathic Hemolytic Anemia." Case Reports in Oncology 12, no. 1 (2019): 104–8. http://dx.doi.org/10.1159/000494753.

Full text

Abstract:

Hemolytic anemia in the setting of malignancy is a rare manifestation of paraneoplastic syndrome with significant morbidity. Here we discuss a case involving metastatic breast cancer presenting with severe hemolytic anemia and renal failure secondary to thrombotic microangiopathy of malignancy. This case discusses the workup for secondary hemolytic anemia, a possible role for therapeutic plasma exchange in this setting, as well the current understanding of the management of microangiopathic hemolytic anemia of malignancy.

APA, Harvard, Vancouver, ISO, and other styles

7

Tulai, Iulia M., Oana M. Penciu, Raymond Raut, and Alla Rudinskaya. "Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy." Texas Heart Institute Journal 46, no. 1 (2019): 48–52. http://dx.doi.org/10.14503/thij-17-6472.

Full text

Abstract:

Thrombotic microangiopathic syndromes are characterized by thrombus formation leading to microangiopathic hemolytic anemia, thrombocytopenia, and end-organ injury that most often affects the kidney and brain. Patients with thrombotic microangiopathy can also present with cardiac involvement, which has been shown to worsen their prognosis. We describe the case of a 46-year-old woman who presented with acute congestive heart failure as a manifestation of catastrophic antiphospholipid syndrome, which is characterized by rapidly progressing multiorgan involvement. Targeted therapy improved our pat

APA, Harvard, Vancouver, ISO, and other styles

8

Skwierawska, Kamila, Krzysztof Woźniak, Anna Waszczuk-Gajda, et al. "Cancer-related microagiopathic hemolytic anemia in a patient with breast cancer – diagnostic difficulties." OncoReview 10, no. 4(40) (2020): 134–38. http://dx.doi.org/10.24292/01.or.420231220.

Full text

Abstract:

Cancer-related microangiopathic hemolytic anemia is rarely recognized as a paraneoplastic syndrome with a very poor prognosis in cancer patients. The treatment and prognosis are significantly different from that in other thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. The case of described patient demonstrates the diagnostic difficulties in diagnosing the causes of hemolytic anemia in patient with breast cancer and appropriate treatment.

APA, Harvard, Vancouver, ISO, and other styles

9

Özsoylu, Şinasi. "About Microangiopathic Hemolytic Anemia." Turkish Journal of Hematology 32, no. 1 (2015): 92. http://dx.doi.org/10.4274/tjh.2014.0382.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Morton, Jordan M., and James N. George. "Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer." Journal of Oncology Practice 12, no. 6 (2016): 523–30. http://dx.doi.org/10.1200/jop.2016.012096.

Full text

Abstract:

The unexpected occurrence of thrombotic microangiopathy (TMA), characterized by microangiopathic hemolytic anemia and thrombocytopenia, in a patient with cancer requires urgent diagnosis and appropriate management. TMA is a term used to describe multiple syndromes caused by microvascular thrombosis, including thrombotic thrombocytopenic purpura (TTP), Shiga toxin–mediated hemolytic uremic syndrome, and complement-mediated TMA. In patients with cancer, systemic microvascular metastases and bone marrow involvement can cause microangiopathic hemolytic anemia and thrombocytopenia. This occurs most

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Microangiopathic Anemia"

1

PIHAN, ISABELLE. "Anemie hemolytique microangiopathique dans les cancers : a propos de neuf observations avec revue de la litterature." Amiens, 1989. http://www.theses.fr/1989AMIEM072.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

LE, GUELTE ANNE. "L'anemie hemolytique par microangiopathie dans les tumeurs solides de l'adulte." Lyon 1, 1989. http://www.theses.fr/1989LYO1M368.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

BAUZA, FRANCOISE. "Reflexions sur le hellp syndrome." Aix-Marseille 2, 1989. http://www.theses.fr/1989AIX20201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Chao, Shih-Hsuan, and 趙師萱. "Efficacy and Safety of Rituximab in Autoimmune and Microangiopathic Hemolytic Anemia: A Systematic Review and Meta-analysis." Thesis, 2019. http://ndltd.ncl.edu.tw/handle/xp9h5e.

Full text

Abstract:

碩士<br>國立陽明大學<br>藥理學研究所<br>107<br>Background: Hemolytic anemia (HA) is a kind of anemia due to the destruction of red blood cells (RBC) from the circulation before their normal life span. Location of RBC destruction occurs varied, such as in larger vessels (eg. autoimmune hemolytic anemia, AIHA) or smaller vessels (eg. microangiopathic hemolytic anemia, MAHA). AIHA is a rare disease caused by autoantibodies directed against erythrocyte self-antigens, and its thermal-based classification is based on the optimal autoantibody-RBC reactivity temperature. MAHA is non-immune hemolysis resulting from

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Microangiopathic Anemia"

1

Gupta, Arun. "Microangiopathic Hemolytic Anemia." In Decision Making Through Problem Based Learning in Hematology. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-8933-1_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Nahid, Seema, Fateen Shareef, Azha Fatima, Umm E. Amara, Umme Nashrah, and Ifrah Fatima. "Microangiopathic Hemolytic Anemia of Pregnancy: Facts and Figures." In Updates in Intensive Care of OBGY Patients. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-9577-6_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Singh, Aakanksha, and Mrinalini Kotru. "Laboratory Diagnosis of Microangiopathic Hemolytic Anemia Including TTP, DIC, and HUS." In Hematopathology. Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-7713-6_7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mallouh, Ahmad A. "Microangiopathic Hemolytic Anemias." In Textbook of Clinical Pediatrics. Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-02202-9_323.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Shenkman, Boris, Yulia Einav, and Ophira Salomon. "Thrombotic Thrombocytopenic Purpura and Other Thrombotic Microangiopathic Hemolytic Anemias." In Diagnostic Criteria in Autoimmune Diseases. Humana Press, 2008. http://dx.doi.org/10.1007/978-1-60327-285-8_101.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Shenkman, Boris, Yulia Einav, Ophira Salomon, Yehuda Shoenfeld, Rocio Morán Contla, and Abihai Lucas Hernández. "Thrombotic Thrombocytopenic Purpura and Other Thrombotic Microangiopathic Hemolytic Anemias." In Autoimmune Disease Diagnosis. Springer Nature Switzerland, 2024. https://doi.org/10.1007/978-3-031-69895-8_109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

"Microangiopathic Hemolytic Anemia." In Diagnostic Pathology: Blood and Bone Marrow. Elsevier, 2018. http://dx.doi.org/10.1016/b978-0-323-39254-9.50018-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Tsai, H. M. "Microangiopathic Hemolytic Anemia." In Reference Module in Biomedical Sciences. Elsevier, 2014. http://dx.doi.org/10.1016/b978-0-12-801238-3.00069-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

"Microangiopathic Hemolytic Anemia." In Dictionary of Toxicology. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-9283-6_1735.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Kaufman, Lewis. "Thrombotic Microangiopathies." In Kidney Protection, edited by Vijay Lapsia, Bernard G. Jaar, and A. Ahsan Ejaz. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780190611620.003.0032.

Full text

Abstract:

The thrombotic microangioapathy (TMA) syndromes are characterized by concomitant occurrence of severe thrombocytopenia, microangiopathic hemolytic anemia, and ischemic end organ dysfunction often of the kidneys. While several of their features overlap in terms of clinical presentation, the pathophysiology and underlying causes of each form of primary TMA are quite unique. Over the last decade, researchers’ understanding of these underlying causes has accelerated dramatically, providing transformative approaches to the way patients with these disorders are diagnosed, followed, stratified, and t

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Microangiopathic Anemia"

1

Bedient, Timothy J., and Edward C. Dempsey. "Microangiopathic Hemolytic Anemia From Occult Adenocarcinoma." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4608.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Santos, João Vitor Ribeiro dos, Mariana Spitz, and Ana Carolina Andorinho. "Stroke secondary to thrombotic microangiopathy." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.300.

Full text

Abstract:

Introduction: Thrombotic thrombocytopenic purpura (TTP) is a hematological disease resulting from the ADAMTS 13 plasmatic protein deficit. It can be congenital or sporadic, and is usually autoimmune. Pathological platelet adhesion occurs, leading to microthrombi in capillary and arterial circulation, microangiopathic anemia and ischemia. The clinical picture includes thrombocytopenia, renal dysfunction, fluctuating neurological symptoms, microangiopathic hemolytic anemia, and fever. Methods: Case report of a 51-year-old male hypertensive patient, diagnosed with idiopathic thrombocytopenic purp

APA, Harvard, Vancouver, ISO, and other styles

3

Biegelmeyer, Erika, Julia Boechat Farani, Evelise Mileski do Amaral Berlet, Marcel Mathias Villaça, Marília Voges de Souza, and Cristina Ferreira Rabelo. "Intestinal vasculitis, mesenteritis, microangiopathic anemia and alveolar hemorrhage: a severe presentation of dermatomyositis." In SBR 2021 Congresso Brasileiro de Reumatologia. Sociedade Brasileira de Reumatologia, 2021. http://dx.doi.org/10.47660/cbr.2021.2089.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Lim, Brian F., Andrew Caravello, James A. Espinosa, and Alan Lucerna. "Case Report: A Case of TTP in the ED." In 28th Annual Rowan-Virtua Research Day. Rowan University Libraries, 2024. http://dx.doi.org/10.31986/issn.2689-0690_rdw.stratford_research_day.64_2024.

Full text

Abstract:

We report a case of a 54-year-old female who presented with mild shortness of breath, lower chest discomfort, fatigue, and weakness ongoing for several days and was diagnosed with thrombotic thrombocytopenic purpura (TTP). TTP is characterized by microangiopathic hemolytic anemia and thrombocytopenia due to either an inherited or immune-mediated reduction in von Willebrand Factor (VWF) cleaving protease ADAMTS13. Patients presenting with non-specific symptoms is becoming increasingly common and initial bias could be to attribute symptoms to viral syndrome or upper respiratory tract infection.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!